{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:11:15Z","timestamp":1762985475474,"version":"3.45.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["fertstertscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Science"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.xfss.2023.06.003","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:15:32Z","timestamp":1688994932000},"page":"317-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-4447","authenticated-orcid":false,"given":"Ayman","family":"Al-Hendy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying F.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Faustmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Groettrup-Wolfers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisa","family":"Laapas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Parke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfss.2023.06.003_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12905-019-0726-1","article-title":"Heavy menstrual bleeding among women aged 18\u201350 years living in Beijing, China: prevalence, risk factors, and impact on daily life","volume":"19","author":"Ding","year":"2019","journal-title":"BMC Women's Health"},{"key":"10.1016\/j.xfss.2023.06.003_bib2","first-page":"665","article-title":"The prevalence of menstrual disorders in Iran: a systematic review and meta-analysis","volume":"16","author":"Omani Samani","year":"2018","journal-title":"Int J Reprod Biomed"},{"key":"10.1016\/j.xfss.2023.06.003_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijgo.2014.09.027","article-title":"Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey","volume":"128","author":"Fraser","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.xfss.2023.06.003_bib4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/1471-0528.14640","article-title":"Epidemiology of uterine fibroids: a systematic review","volume":"124","author":"Stewart","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.xfss.2023.06.003_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.633180","article-title":"Understanding the impact of uterine fibroids on human endometrium function","volume":"9","author":"Navarro","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.xfss.2023.06.003_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jpsychores.2014.12.016","article-title":"Beyond the physical: a qualitative assessment of the burden of symptomatic uterine fibroids on women's emotional and psychosocial health","volume":"78","author":"Ghant","year":"2015","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.xfss.2023.06.003_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197958","article-title":"Investigating the loss of work productivity due to symptomatic leiomyoma","volume":"13","author":"Hasselrot","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.xfss.2023.06.003_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-0037-1607264","article-title":"Uterine fibroids: burden and unmet medical need","volume":"35","author":"Al-Hendy","year":"2017","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.xfss.2023.06.003_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib11","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/AOG.0000000000002942","article-title":"Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Liu","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2023.06.003_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/AOG.0000000000002462","article-title":"Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial","volume":"131","author":"Simon","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2023.06.003_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfss.2023.06.003_bib15","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/AOG.0000000000002933","article-title":"Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Carr","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2023.06.003_bib16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/AOG.0000000000003869","article-title":"Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas","volume":"135","author":"Simon","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2023.06.003_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfss.2023.06.003_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial","volume":"133","author":"Osuga","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2023.06.003_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12325-020-01555-z","article-title":"Medical therapy for fibroids: what next for ulipristal acetate?","volume":"38","author":"Ekanem","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.xfss.2023.06.003_bib25","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/cmdc.201800487","article-title":"Discovery of vilaprisan (BAY 1002670): a highly potent and selective progesterone receptor modulator optimized for gynecologic therapies","volume":"13","author":"M\u00f6ller","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.xfss.2023.06.003_bib26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2018.10.012","article-title":"Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study","volume":"111","author":"Bradley","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/humrep\/dew140","article-title":"Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women","volume":"31","author":"Sch\u00fctt","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfss.2023.06.003_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jcph.998","article-title":"Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women","volume":"58","author":"Sch\u00fctt","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xfss.2023.06.003_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejogrb.2020.05.043","article-title":"Efficacy and safety of vilaprisan in women with uterine fibroids: data from the phase 2b randomized controlled trial ASTEROID 2","volume":"252","author":"Gemzell-Danielsson","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.xfss.2023.06.003_bib30","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/humrep\/det247","article-title":"BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies","volume":"28","author":"Wagenfeld","year":"2013","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfss.2023.06.003_bib31","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40264-020-00960-1","article-title":"An evaluation of postmarketing reports of serious idiosyncratic liver injury associated with ulipristal acetate for the treatment of uterine fibroids","volume":"43","author":"Kang","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.xfss.2023.06.003_bib32","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/j.fertnstert.2018.07.189","article-title":"Efficacy and safety of the selective progesterone receptor modulator vilaprisan - 24-week outcomes from ASTEROID 2 study.","volume":"110","author":"Gemzell-Danielsson","year":"2018","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib33","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.fertnstert.2010.03.061","article-title":"Menstrual blood loss measurement: validation of the alkaline hematin technique for feminine hygiene products containing superabsorbent polymers","volume":"94","author":"Magnay","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.fertnstert.2011.05.096","article-title":"Validation of a rapid alkaline hematin technique to measure menstrual blood loss on feminine towels containing superabsorbent polymers","volume":"96","author":"Magnay","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s41687-020-00263-0","article-title":"Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies","volume":"4","author":"Haberland","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.xfss.2023.06.003_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0015-0282(01)01847-7","article-title":"Determination of total menstrual blood loss","volume":"76","author":"Wyatt","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.fertnstert.2013.10.051","article-title":"Validation of a new menstrual pictogram (superabsorbent polymer-c version) for use with ultraslim towels that contain superabsorbent polymers","volume":"101","author":"Magnay","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib38","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.fertnstert.2013.08.028","article-title":"A new menstrual pictogram for use with feminine products that contain superabsorbent polymers","volume":"100","author":"Magnay","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2023.06.003_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jval.2011.07.007","article-title":"Further validation of the uterine fibroid symptom and quality-of-life questionnaire","volume":"15","author":"Coyne","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.xfss.2023.06.003_bib40","first-page":"290","article-title":"The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata","volume":"99","author":"Spies","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2023.06.003_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6874-12-6","article-title":"Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women","volume":"12","author":"Zimmermann","year":"2012","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.xfss.2023.06.003_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-021-01073-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of the selective progesterone receptor modulator vilaprisan: a comprehensive overview","volume":"61","author":"Schultze-Mosgau","year":"2022","journal-title":"Clin Pharmacokinet"}],"container-title":["F&S Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666335X2300037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666335X2300037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:08:13Z","timestamp":1762981693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666335X2300037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2666335X2300037X"],"URL":"https:\/\/doi.org\/10.1016\/j.xfss.2023.06.003","relation":{},"ISSN":["2666-335X"],"issn-type":[{"type":"print","value":"2666-335X"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"F&S Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfss.2023.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}